Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123)

NCT00113282 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

57

Enrollment

OTHER_GOV

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Interleukin-2 (IL-2)

Sponsor

French National Agency for Research on AIDS and Viral Hepatitis

Collaborators

[object Object]